Abstract: Methods of assessing and reducing risk of graft versus host disease (GVHD) based on gene expression profiling are described, as well as methods of selecting a suitable transplant donor. Corresponding reagents and kits are also described.

Abstract: Methods of assessing and reducing risk of graft versus host disease (GVHD) based on gene expression profiling are described, as well as methods of selecting a suitable transplant donor. Corresponding reagents and kits are also described.

Abstract: Methods of assessing and reducing risk of graft versus host disease (GVHD) based on gene expression profiling are described, as well as methods of selecting a suitable transplant donor. Corresponding reagents and kits are also described.

Abstract: The invention relates to predicting or determining risk of a hematopoietic cell transplant (HCT) from a donor to induce Graft vs. Host Disease (GVHD) in a HCT recipient; to classifying HCT from a candidate donor according to the risk of inducing GVHD in a HCT recipient; and to organizational constructs (e.g., databases) and methods of producing organizational constructs (e.g., databases) in which HCT of one or more candidate donors is classified or scored according to risk of inducing GVHD in a HCT recipient. The invention also relates to kits and arrays useful for predicting or determining risk of HCT from a candidate donor to induce GVHD in a HCT recipient, and for classifying or scoring such donors according to risk of inducing GVHD in a HCT recipient.

Abstract: Methods of assessing and reducing risk of graft versus host disease (GVHD) based on gene expression profiling are described, as well as methods of selecting a suitable transplant donor. Corresponding reagents and kits are also described.

Abstract: Methods of assessing and reducing risk of graft versus host disease (GVHD) based on gene expression profiling are described, as well as methods of selecting a suitable transplant donor. Corresponding reagents and kits are also described.

Abstract: Assays, kits, methods and systems for predicting outcome in patients with follicular lymphoma based upon measurement of one or more phenomenologically competitive or synergistic gene pairs or a set of classifier genes are provided.

Abstract: Methods of assessing and reducing risk of graft versus host disease (GVHD) based on gene expression profiling are described, as well as methods of selecting a suitable transplant donor. Corresponding reagents and kits are also described.

Abstract: A method, system, computer program selecting attribute sets of characterizing attributes of an object, selecting an attribute set of attributes of interest, assigning a likelihood for each characterized attribute set that the attribute set occurs when the attribute set of interest occurs (each likelihood determined using Bayesian computable classifiers on a dataset of attributes for actual samples), comparing each assigned likelihood against likelihood thresholds, and reporting the assigned likelihoods of the characterizing attribute set based on the likelihood thresholds. Markers may be identified for diagnosis and prognosis. Characterizing attributes may be gene expression levels and the attribute of interest may be drug sensitivity level, drug dose (absolute concentration or dose relative to some standard dose), dose of drug which causes half-maximal cellular growth rate, or logarithm base 10 (dose) where dose is the dose which yields half-maximal total cell mass accumulating.

Abstract: The present invention relates to purified polynucleotides and compositions comprising pluralities of polynucleotides that are differentially expressed during foam cell development and are associated with atherosclerosis. The present invention presents the use of the compositions as elements on a substrate, and provides methods for using the compositions and polynucleotides.